Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
Abstract Inhaled treprostinil was approved recently for interstitial lung disease‐pulmonary hypertension; however, efficacy in “real‐world” populations is not known. We designed a protocol and report our experience evaluating 10 patients referred for therapy. Misdiagnosis at presentation was common;...
Main Authors: | Shelsey W. Johnson, Lauren Finlay, Stephen C. Mathai, Ronald H. Goldstein, Bradley A. Maron |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-07-01
|
Series: | Pulmonary Circulation |
Subjects: | |
Online Access: | https://doi.org/10.1002/pul2.12126 |
Similar Items
-
Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
by: Adam J. Plaunt, et al.
Published: (2021-01-01) -
INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
by: Nicholas S. Hill, et al.
Published: (2022-07-01) -
Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
by: John W. Swisher, PhD, MD, et al.
Published: (2017-01-01) -
Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension
by: Pugliese SC, et al.
Published: (2016-01-01) -
Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
by: Julia McSweeney, et al.
Published: (2023-04-01)